1. Johansson, S.G., et al., Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol, 2004. 113(5): p. 832-6.

2. Kay, A.B., Allergy and allergic diseases. 2008, Oxford: Blackwell Science.

3. Ishizaka, K., T. Ishizaka, and M.M. Hornbrook, Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol, 1966. 97(1): p. 75-85.

4. Johansson, S.G. and H. Bennich, Immunological studies of an atypical (myeloma) immunoglobulin. Immunology, 1967. 13(4): p. 381-94

5. Larche, M., D.S. Robinson, and A.B. Kay, The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol, 2003. 111(3): p. 450-63; quiz 464.

6. Ali, F.R., A.B. Kay, and M. Larche, Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. Thorax, 2007. 62(9): p. 750-57.

7. Nilsson, O.B., M. van Hage, and H. Gronlund, Mammalian-derived respiratory allergens - implications for diagnosis and therapy of individuals allergic to furry animals. Methods, 2014. 66(1): p. 86-95.

8. Moffatt, M.F., et al., A large-scale, consortium-based genomewide association study of asthma. N Engl J Med, 2010. 363(13): p. 1211-21.

9. Xavier, R.J. and J.D. Rioux, Genome-wide association studies: a new window into immune-mediated diseases. Nat Rev Immunol, 2008. 8(8): p. 631-43.

10. Ahluwalia, S.K. and E.C. Matsui, The indoor environment and its effects on childhood asthma. Curr Opin Allergy Clin Immunol, 2011. 11(2): p. 137-43.

11. Aalberse, R.C. and R. Crameri, IgE-binding epitopes: a reappraisal. Allergy, 2011. 66(10): p. 1261-74.

12. Ferreira, F., et al., Allergic cross-reactivity: from gene to the clinic. Allergy, 2004. 59(3): p. 243-67.

13. Aalberse, R.C., J. Akkerdaas, and R. van Ree, Cross-reactivity of IgE antibodies to allergens. Allergy, 2001. 56(6): p. 478-90.

14. Breiteneder, H., Protein families: implications for allergen nomenclature, standardisation and specific immunotherapy. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, 2009. 96: p. 249-54; discussion 254-6.

15. Morris, D.O., Human allergy to environmental pet danders: a public health perspective. Vet Dermatol, 2010. 21(5): p. 441-9.

16. Okada, H., et al., The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol, 2010. 160(1): p. 1-9.

17. Munir, A.K., et al., Allergens in school dust. I. The amount of the major cat (Fel d I) and dog (Can f I) allergens in dust from Swedish schools is high enough to probably cause perennial symptoms in most children with asthma who are sensitized to cat and dog. J Allergy Clin Immunol, 1993. 91(5): p. 1067-74.

18. Cai, G.H., et al., Fungal DNA and pet allergen levels in Swedish day care centers and associations with building characteristics. J Environ Monit, 2011. 13(7): p. 2018-24.

19. Gronlund, H., et al., Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-allergic children with asthma compared with rhinoconjunctivitis. Clin Exp Allergy, 2008. 38(8): p. 1275-81.

20. Gronlund, H., et al., Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem, 2003. 278(41): p. 40144-51.

21. Gronlund, H., et al., The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol, 2010. 151(4): p. 265-74.

22. Konieczny, A., et al., The major dog allergens, Can f 1 and Can f 2, are salivary lipocalin proteins: cloning and immunological characterization of the recombinant forms. Immunology, 1997. 92(4): p. 577-86.

23. Nilsson O.B., Binnmyr J, Zoltowska A, Saarne T, van Hage M, Grönlund H. Characterization of the dog lipocalin allergen Can f 6: the role in cross-reactivity with cat and horse. Allergy 2012. 67(6) p. 751-7.

24. Mattsson, L., et al., Prostatic kallikrein: a new major dog allergen. J Allergy Clin Immunol, 2009. 123(2): p. 362-8.

25. Valenta, R., et al., Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy, 2011.

26. Haugaard, L., R. Dahl, and L. Jacobsen, A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol, 1993. 91(3): p. 709-22.

27. Hedlin, G., et al., Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol, 1991. 87(5): p. 955-64.

28. Vredegoor, D.W., et al. (2012) Can f 1 levels in hair and homes of different dog breeds: Lack of evidence to describe any dog breed as hypoallergenic. J Allergy Clin Immunol,  DOI: S0091-6749(12)00793-2 [pii]10.1016/j.jaci.2012.05.013.

29. Hiller, R., et al., Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J, 2002. 16(3): p. 414-6.

30. Shreffler, W.G., Microarrayed recombinant allergens for diagnostic testing. J Allergy Clin Immunol, 2011. 127(4): p. 843-9; quiz 850-1.

31. Madhurantakam, C., et al., Crystal structure of the dog lipocalin allergen Can f 2: implications for cross-reactivity to the cat allergen Fel d 4. J Mol Biol, 2010. 401(1): p. 68-83.

32. Smith, W., et al., Two newly identified cat allergens: the von Ebner gland protein Fel d 7 and the latherin-like protein Fel d 8. Int Arch Allergy Immunol, 2011. 156(2): p. 159-70.

33. Spitzauer, S., et al., Molecular characterization of dog albumin as a cross-reactive allergen. J Allergy Clin Immunol, 1994. 93(3): p. 614-27.

34. van Ree, R., et al., Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. J Allergy Clin Immunol, 1999. 104(6): p. 1223-30.

35. Spitzauer, S., et al., IgE cross-reactivities against albumins in patients allergic to animals. J Allergy Clin Immunol, 1995. 96(6 Pt 1): p. 951-9.

36. Goubran Botros, H., et al., Cross-antigenicity of horse serum albumin with dog and cat albumins: study of three short peptides with significant inhibitory activity towards specific human IgE and IgG antibodies. Immunology, 1996. 88(3): p. 340-7.

37. Nilsson, O.B., et al., Characterization of the dog lipocalin allergen Can f 6: the role in cross-reactivity with cat and horse. Allergy, 2012. 67(6): p. 751-7.

38. Mattsson, L., et al., Molecular and immunological characterization of Can f 4: a dog dander allergen cross-reactive with a 23 kDa odorant-binding protein in cow dander. Clin Exp Allergy, 2010. 40(8): p. 1276-87.

39. Weidinger, S., et al., Prostate-specific antigen as allergen in human seminal plasma allergy. J Allergy Clin Immunol, 2006. 117(1): p. 213-5.

40. Nilsson, O.B., et al., In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One, 2011. 6(9): p. e24558.